Navigation Links
MDS Analytical Technologies' Laser Capture Microdissection Helps Facilitate Discovery of Potential New Colon-Cancer Biomarker

SUNNYVALE, CA, Feb. 4 /PRNewswire-FirstCall/ - MDS Analytical Technologies, a leader in innovative solutions for drug discovery and life sciences research, today announced that its Arcturus(R) Laser Capture Microdissection (LCM) instruments were used by researchers at the University of Cincinnati (UC) in their discovery of genetic variations that may prove to be key predictors of risk for colon cancer and indicators of the disease's progression.

Researchers hope that these important findings will provide doctors with much improved diagnostic tools for colon cancer. By identifying people that carry these genetic variations, doctors will be better equipped to determine the course of treatment for patients with the disease. This data may also prove important as doctors advise patients on health and lifestyle choices that may influence one's risk of developing the disease.

"MDS Analytical Technologies is very pleased that its Arcturus line of LCM instruments played such a key role in this important discovery that may move us even closer to preventing more people from developing colon cancer," said Andy Boorn, President of MDS Analytical Technologies. "By maintaining custody of the sample throughout the microdissection process, the Arcturus system removed any guesswork from the experiment, and allowed the researchers at the University of Cincinnati to collect only their desired material for this important study."

As reported in the January 16, 2009 issue of PLoS Genetics, a peer-review, open-access scientific journal published by the U.S. Public Library of Science, scientists at UC used Arcturus(R) LCM systems to investigate the role that the abnormal regulation of a known prostate cancer biomarker - alpha-methylacyl-coenzyme A racemase (AMACR) - plays in colon cancer. AMACR is a protein that breaks down branched-chain fatty acids, which are found in red meats and dairy products, and are suspected to be risk factors for the disease.

"AMACR was recently shown to have abnormal expression patterns in colon cancer, but not much was known about how it's regulated at the gene level," said Shuk-mei Ho, Ph.D., Chair of UC's Department of Environmental Health and senior author of the study. "Uncovering how the gene is abnormally activated in cancer will give us a better understanding of how to treat the disease in the end."

To find answers, scientists at UC, along with researchers at the University of Massachusetts, used Arcturus(R) LCM instruments to enrich a homogenous population of cancer cells from colon carcinoma tissue, so that their data would not be obscured by non-carcinoma material that otherwise would be included in the analysis. Scientists analyzed a series of samples that represented the entire colon cancer progression, comparing the genetic sequences of the laser capture microdissected colon carcinoma cells with sequences from a general population. Comparative sequencing of the two groups of samples revealed the genetic variations that may be the triggers for abnormal protein expression found in colon cancer.

"Only by using LCM were we able to uncover these deletions in the AMACR sequence," Dr. Ho said. "We needed to look at only the cancer cells versus normal cells, and LCM was the only way to achieve this level of sensitivity."

In addition to the novel deletions, the study identified putative transcription factors that, under normal circumstances, may bind to the deleted sequence to regulate gene expression. The study also found a novel genetic variant in AMACR that is present in the general population, and which may influence the course of how colon cancer may progress.

"We need to start paying closer attention to how the environment in which we live and the things we put in our bodies interact with our genetic makeup to influence our cancer risk," Dr. Ho added.

The UC research team expects to expand this research into a multi-center study in the near future. The project is currently funded by the National Institutes of Health and the U.S. Army Prostate Cancer Program.

ArcturusXT(TM) System

MDS Analytical Technologies will present the ArcturusXT(TM) system at the American Academy of Forensic Sciences Annual Meeting 2009, February 18-20 in Denver, CO (MDS Analytical Technologies' booth # 606). The system will also be presented at the American Association for Cancer Research Annual Meeting 2009, April 19-22 in Denver, CO (MDS Analytical Technologies' booth # 546).

About Arcturus(R) LCM Instruments

The Arcturus(R) LCM instruments isolate pure cell populations from heterogeneous populations of cells by employing MDS Analytical Technologies' exclusive infrared (IR) laser-based capture technology, which has been designed to maintain biomolecule integrity within the microdissected samples for use in downstream analyses. Whether researchers are using LCM alone or in combination with the ultraviolet laser cutting option, the gentle non-damaging IR capture technology allows the custody of the microdissected sample to be maintained throughout the process. This gives researchers confidence and assurance that their desired material has been collected. Enrichment of specific populations of cells through this process enables researchers to perform sensitive and specific molecular analyses, otherwise not possible without the use of LCM. Arcturus(R) LCM instruments are for research use only and not intended for clinical or diagnostic purposes.

About MDS Analytical Technologies

MDS Analytical Technologies, a business unit of MDS Inc., is focused on the research, design, manufacture and marketing of state-of-the-art tools for mass-spectrometry, drug discovery and bioresearch. MDS Analytical Technologies' products are designed to help accelerate the complex process of discovering and developing new drug compounds, and are sold to research scientists around the world. The mass-spectrometer product lines are also sold globally through joint ventures with two of the world's leading analytical instrumentation and life sciences companies, Life Technologies Corp. and PerkinElmer, Inc. Find out more at or

About MDS Inc.

MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life-sciences company that provides market-leading products and services that our customers need for the development of drugs, and the diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 5,000 highly skilled people in 29 countries. Find out more at or by calling 1-888-MDS-7222, 24 hours a day.

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Polymathic Analytical Labs Launches New Website
2. Patheon Opens New U.S. Headquarters and Analytical Laboratory Facility in Research Triangle Park, NC
3. Frost & Sullivan Recognizes Waters Corporation for Its Pioneering, High Customer Value Analytical Instrumentation Product, SYNAPT HDMS
4. Associates of Cape Cod (ACC) and MDS Analytical Technologies Collaborate to Offer a More Robust LAL Endotoxin Assay Platform
5. MDS Analytical Technologies Acquires Blueshift Biotechnologies
6. Pace Analytical Services, Inc., Purchases Laucks Testing Laboratory, Inc.
7. Neurobiological Technologies Announces Appointment of William A. Fletcher as Acting CEO
8. Dilon Technologies Slant15(TM) and LEHR Collimators Enhance Imaging Capabilities
9. Patient Safety Technologies Closes $2.55 Million Financing
10. Palomar Medical Technologies to Host Fourth Quarter and Year End 2008 Financial Results Conference Call and Webcast on February 5, 2009
11. Medusa Medical Technologies Announces Integration of Siren ePCR Suite(TM) with Philips HeartStart MRx Monitor/Defibrillator
Post Your Comments:
(Date:11/29/2015)... Viejo, CA (PRWEB) , ... November 29, 2015 ... ... an all new and unique analog distortion effect tool designed specially for Final ... their footage, and create limiltess looks with the easy-to-use modification controls. Destoying and ...
(Date:11/28/2015)... ... , ... Safe storage for contraceptive devices may not always be easy to ... and the other from Bradley Beach, New Jersey, there is an easy solution to ... to replace NuvaRings more often than necessary. As such, it affords peace of mind ...
(Date:11/27/2015)... (PRWEB) , ... November 28, 2015 , ... There is ... we outperform our billings from last year? , This question has not been an ... are coming to the retirement age and the younger workforce don’t share the same ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... in America. As people age, more care is needed, especially with Alzheimer’s, dementia ... medical professionals are being overworked. The forgotten part of this equation: 80 percent ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Lizzie’s Lice ... The company is offering customers 10% off of their purchase of lice treatment product. ... at full price. According to a company spokesperson. “Finding lice is a sure way ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... Pays-Bas, November 27, 2015 ... traitement photodynamique au Bremachlorin contre le cancer avancé. ... consistant à combiner l,immunothérapie au traitement photodynamique au ... --> Une nouvelle approche consistant à ... le cancer avancé.    Clinical ...
(Date:11/27/2015)... 26, 2015 ... the "2016 Global Tumor Marker Testing ... and Sales Segment Forecasts, Innovative Technologies, Instrumentation ... to their offering. --> ... "2016 Global Tumor Marker Testing Market: ...
(Date:11/26/2015)... November 26, 2015 ... nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie ... ) --> ... (Photo: ) ... Medisch Centrum (LUMC) blijkt ...
Breaking Medicine Technology: